"Becca McCarthy says she's always been good at recognizing when something is about to break into the mainstream. She has spent her career inside startups, helping turn early interest into real markets and building products before most people realize there's demand for them. That's why, a few years ago, when she started hearing people in her network talking about GLP-1 drugs, she paid attention."
"But McCarthy was hearing about them long before they became cultural shorthand. Her otherwise healthy friends and family were injecting these drugs for weight loss and keeping it mostly to themselves. Using a medication designed for diabetes to manage appetite carried a stigma. It was considered cheating and ran counter to the wellness world's insistence on clean eating, discipline, and willpower."
Evolv co-founder Becca McCarthy recognized early signals of widespread off-label GLP‑1 use for weight loss and the stigma surrounding injections and prescriptions. GLP‑1 drugs like Ozempic and Zepbound became rapidly growing prescription medicines, driving substantial demand and cultural secrecy. McCarthy pursued a nonpharmaceutical solution to provide GLP‑1–like appetite control without needles, prescriptions, or synthetic hormones. In 2023, McCarthy partnered with molecular biologist Dr. Corey Henderson to develop a natural, oral approach based on a novel peptide interacting with GLP‑1 and GIP receptors. The product aims to deliver efficacy while avoiding clinical and social barriers to GLP‑1 drugs.
Read at Entrepreneur
Unable to calculate read time
Collection
[
|
...
]